Latest & greatest articles for menopause

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on menopause or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on menopause and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for menopause

101. Bishosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures

Bishosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures Bisphosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures – TheNNTTheNNT Bisphosphonates for Fracture Prevention in Post-Menopausal Women Without Prior Fractures No benefit found In Summary, for those who took the bisphosphonates: Benefits in NNT 100% saw no benefit after 3 years of treatment None were helped (fracture prevented after 3 years of medicine) Harms in NNT A small

theNNT2011

102. Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density

Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or Very Low Bone Density – TheNNTTheNNT Bisphosphonates for Fracture Prevention in Post-Menopausal Women With Prior Fractures or With Very Low Bone Density 100 for hip fracture In Summary, for those who took the bisphosphonates: Benefits in NNT 94% saw no benefit after 3 years of treatment 5% avoided

theNNT2011

103. Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial

Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized, placebo-controlled trial 21078629 2011 02 22 2012 02 21 2013 11 21 1462-0332 50 3 2011 Mar Rheumatology (Oxford, England) Rheumatology (Oxford) Hormonal replacement therapy does not affect self-estimated pain or experimental pain responses in post-menopausal women suffering from fibromyalgia: a double-blind, randomized (...) as self-estimated pain in women suffering from FM. Twenty-nine post-menopausal women were randomized to either 8 weeks of treatment with transdermal 17β-oestradiol (50 µg/day) or placebo according to a double-blind protocol. A self-estimation of pain, a set of quantitative sensory tests measuring thresholds to temperature, thermal pain, cold pain and pressure pain, and a cold pressor test were performed on three occasions: before treatment, after 8 weeks of treatment and 20 weeks after cessation

EvidenceUpdates2011

104. WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles.

WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. BACKGROUND: hMG and recombinant FSH, have both been used successfully for controlled ovarian hyperstimulation in in vitro fertilization and embryo transfer (IVF-ET). OBJECTIVES: To compare the effectiveness of hMG with rFSH in ovarian stimulation protocols in IVF or ICSI treatment cycles. SEARCH STRATEGY: We searched the Cochrane Menstrual Disorders

Cochrane2011

106. Odanacatib for post-menopausal osteoporosis ? first or second line

Odanacatib for post-menopausal osteoporosis ? first or second line Odanacatib for post-menopausal osteoporosis – first or second line Odanacatib for post-menopausal osteoporosis – first or second line NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Odanacatib for post-menopausal osteoporosis – first or second line. Birmingham

Health Technology Assessment (HTA) Database.2011

107. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women

The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women Hopkins RB, Goeree R, Pullenayegum E, Adachi JD, Papaioannou A, Xie F, Thabane L CRD summary The authors concluded that indirect treatment comparisons (...) indicated teriparatide, zoledronic acid and denosumab had the highest probabilities of being most efficacious for non-vertebral and vertebral fractures. In the absence of direct comparisons, the evidence presented may be the best available. However, the authors' conclusions should be considered tentative given limitations of the evidence and synthesis. Authors' objectives To compare the efficacy of nine osteoporosis medications for reducing fractures in post-menopausal women. Searching Seven databases

DARE.2011

108. Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France

Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France Cotte FE, De Pouvourville G Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study examined the cost-effectiveness of osteoporosis treatment with oral bisphosphonates focusing on the issue of poor persistence in post-menopausal women. The authors concluded that improving persistence with oral bisphosphonate was likely to improve health benefits and reduce costs compared to current levels of treatment adherence

NHS Economic Evaluation Database.2011

109. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial.

Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. 21245182 2011 01 19 2011 01 24 2016 10 19 1538-3598 305 3 2011 Jan 19 JAMA JAMA Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. 267-74 10.1001/jama.2010.2016 Concerns regarding the risks associated with estrogen and progesterone to manage menopausal symptoms have resulted in its declining use and increased interest in nonhormonal treatments (...) with demonstrated efficacy for hot flashes. To determine the efficacy and tolerability of 10 to 20 mg/d escitalopram, a selective serotonin reuptake inhibitor, in alleviating the frequency, severity, and bother of menopausal hot flashes. A multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel group trial that enrolled 205 women (95 African American; 102 white; 8 other) between July 2009 and June 2010. Women received 10 to 20 mg/d of escitalopram or a matching placebo for 8 weeks. Primary

JAMA2011 Full Text: Link to full Text with Trip Pro

110. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.

Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. 21771987 2011 07 20 2011 07 21 2016 10 17 1538-3598 306 3 2011 Jul 20 JAMA JAMA Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. 269-76 10.1001/jama.2011.991 Premenopausal (...) patients with breast cancer are at high risk of premature ovarian failure induced by systemic treatments, but no standard strategies for preventing this adverse effect are yet available. To determine the effect of the temporary ovarian suppression obtained by administering the gonadotropin-releasing hormone analogue triptorelin during chemotherapy on the incidence of early menopause in young patients with breast cancer undergoing adjuvant or neoadjuvant chemotherapy. The PROMISE-GIM6 (Prevention

JAMA2011

111. AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Menopause

AACE Medical Guidelines for Clinical Practice for Diagnosis and Treatment of Menopause 1 AACE Guidelines Neil F. Goodman, MD, FACE; Rhoda H. Cobin, MD, MACE; Samara Beth Ginzburg, MD; Ira A. Katz, MD, FACE; Dwain E. Woode, MD American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice are systematically developed statements to assist health care professionals in medical decision making for specific clinical conditions but are in no way a substitute for a medical (...) for, their best clinical judgment. The presented recommendations may not be appropriate in all situations. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances. Copyright © 2011 AACE.2 AACE Menopause Guidelines Revision Task Force Cochairpersons Neil F . Goodman, MD, F ACE Rhoda H. Cobin, MD, MACE Task Force Members Samara Beth Ginzburg, MD Ira A. Katz, MD, F ACE Dwain E. Woode, MD Reviewers Pauline M. Camacho, MD, F ACE JoAnn E

American Association of Clinical Endocrinologists2011

112. Women's Health Initiative randomised ontrolled trial: Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause

Women's Health Initiative randomised ontrolled trial: Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use (...) treatment within 10 years of menopause Article Text Therapeutics Women's Health Initiative randomised ontrolled trial Combined estrogen plus progestin may reduce coronary heart disease risk after 5 years of use in postmenopausal women starting treatment within 10 years of menopause S. Mitchell Harman Statistics from Altmetric.com No Altmetric data available for this article. Commentary on: Toh S , Hernández-Díaz S , Logan R , et al . Coronary heart disease in postmenopausal recipients of estrogen plus

Evidence-Based Medicine (Requires free registration)2010

113. Evaluation of intervention research in weight reduction in post menopausal women

Evaluation of intervention research in weight reduction in post menopausal women Evaluation of intervention research in weight reduction in post menopausal women Evaluation of intervention research in weight reduction in post menopausal women Al Zadjali M, Keller C, Larkey LK, Albertini L CRD summary The review found that exercise when combined with hypocaloric diet or meal replacement therapy may reduce body weight and fat and improve insulin sensitivity, glycaemic control and cardio (...) approaches that addressed lifestyle behaviours and employed a combination of diet and exercise strategies. Funding Not stated. Bibliographic details Al Zadjali M, Keller C, Larkey LK, Albertini L. Evaluation of intervention research in weight reduction in post menopausal women. Geriatric Nursing 2010; 31(6): 419-434 PubMedID DOI Original Paper URL Indexing Status Subject indexing assigned by NLM MeSH Evidence-Based Nursing; Female; Humans; Postmenopause; Weight Loss AccessionNumber 12011001797 Date

DARE.2010

114. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis

Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A CRD summary This review concluded that black cohosh may reduce the frequency of vasomotor symptoms associated with menopause and that more studies were warranted on its (...) effectiveness and safety. The authors' conclusions appeared to reflect the evidence, but given the likelihood of biases in identifying relevant studies it was difficult to verify these conclusions. Authors' objectives To investigate the efficacy of preparations containing black cohosh on reduction of vasomotor symptoms associated with menopause. Searching English-language studies were identified through a search of PubMed, EMBASE and The Cochrane Library to January 2008. Search terms were reported

DARE.2010

115. Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis

Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis Menopausal hormone therapy and risk of lung cancer: systematic review and meta-analysis Greiser CM, Greiser EM, Doren M CRD summary This review found that ever use of hormone therapy in non-smoking women may increase the risk of adenocarcinoma of the lung and that oestrogen/progestin therapy increased the risk of lung (...) cancer. The first of these conclusions was based on two non-RCT studies of unknown size and quality. The reliability of the conclusions is unclear. Authors' objectives To investigate whether menopausal hormone therapy is related to increasing lung cancer rates in women. Searching MEDLINE, CANCERLIT, EMBASE, Scopus and The Cochrane Library were searched from inception to July 2008. Search terms were reported. Bibliographies of retrieved trials, relevant systematic reviews and previous systematic

DARE.2010

118. Herbal medicines for menopausal symptoms

Herbal medicines for menopausal symptoms Herbal medicines for menopausal symptoms | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Herbal medicines for menopausal symptoms Article Text Reprinted from DTB Herbal medicines for menopausal symptoms Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get

Evidence-Based Nursing (Requires free registration)2010

119. [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women]

[Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Analisis coste-utilidad de los tratamientos farmacologicos para la prevencion de fracturas en mujeres con osteoporosis en Espana [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Analisis coste-utilidad de los tratamientos farmacologicos para la prevencion de fracturas en (...) mujeres con osteoporosis en Espana [Cost-utility analysis of pharmacological treatments for the prevention of bone fractures in osteoporotic post-menopausal Spanish women] Imaz I, Rubio B, Lopez-Delgado ME, Amate JM, Gomez-Pajuelo P, Gonzalez-Enriquez J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Imaz I, Rubio B, Lopez-Delgado ME, Amate JM

Health Technology Assessment (HTA) Database.2010

120. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy

Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen (...) sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy Josefsson ML, Leinster SJ CRD summary This review concluded that women with oestrogen-sensitive early breast cancer who switched to treatment with aromatase inhibitors after two to three years of tamoxifen had improved overall survival compared to those who stayed on tamoxifen for five years. Sequenced therapy appeared to be the preferred treatment regime. Despite poor reporting

DARE.2010